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Abstract
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults; however, the genetic aetiology of the
disease is not yet fully understood. A quantitative expression profile analysis of 157 mature miRNAs was performed on 100
AML patients representing the spectrum of known karyotypes common in AML. The principle observation reported here is
that AMLs bearing a t(15;17) translocation had a distinctive signature throughout the whole set of genes, including the up
regulation of a subset of miRNAs located in the human 14q32 imprinted domain. The set included miR-127, miR-154, miR-
154*, miR-299, miR-323, miR-368, and miR-370. Furthermore, specific subsets of miRNAs were identified that provided
molecular signatures characteristic of the major translocation-mediated gene fusion events in AML. Analysis of variance
showed the significant deregulation of 33 miRNAs across the leukaemic set with respect to bone marrow from healthy
donors. Fluorescent in situ hybridisation analysis using miRNA-specific locked nucleic acid (LNA) probes on cryopreserved
patient cells confirmed the results obtained by real-time PCR. This study, conducted on about a fifth of the miRNAs currently
reported in the Sanger database (microrna.sanger.ac.uk), demonstrates the potential for using miRNA expression to sub-
classify cancer and suggests a role in the aetiology of leukaemia.
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Introduction
Acute myeloid leukaemia (AML) arises from the accumulation
of myeloid precursor cells arrested at early stages of differentiation.
Analysis of the karyotype of leukaemic cells has identified non-
random somatically acquired translocations, inversions, and
deletions, which are often associated with specific subtypes of
AML [1]. The major gene fusion events are the t(8;21), t(15;17),
inv(16), and the 11q23 rearrangements which together account for
approximately 20% of all AMLs and result in the expression of
chimeric proteins.[2]. Of the remaining AMLs, a substantial
proportion, possibly as much as 40% [3], lacks any visible
chromosomal abnormality and cannot be consistently associated
with any known genetic lesion. Large scale clinical studies have
demonstrated that cytogenetic abnormalities provide valuable
information of prognostic relevance. Leukaemias fall into three
broad cytogenetic prognostic risk groups, with the t(8;21), t(15;17),
and inv(16) leukaemias having a more favourable outcome,
whereas those with loss of chromosome 7, deletion of chromosome
5q and more complex karyotypes having an adverse outcome. All
the other subtypes of AML, including those with rearrangement of
11q23 and normal karyotype, have an intermediate prognostic risk
group [3]. Several studies have shown that genome-wide gene
expression profiling can clearly distinguish the major cytogenetic
groups, including normal karyotype samples, identifying specific
sets of genes with expression patterns highly correlated with each
karyotypic class [4–8] and so providing a better understanding of
the underlying disease biology.
A new class of small non-coding RNA molecules, designated as
microRNAs (miRNAs) [9], has been shown to play key roles in a
number of regulatory functions, including modulation of haema-
topoiesis and cell differentiation in mammals [10]. MiRNAs are
single stranded RNAs, typically 19–25 nucleotides in length,
generated from endogenous transcripts and evolutionarily con-
served. They modulate gene expression by complementarity-
mediated binding to target mRNAs resulting in the repression of
translation [11] or in the cleavage of the target transcript [12,13].
There are several indications that miRNAs might be a new class of
genes involved in human tumourigenesis. A proportion of human
miRNA genes is reported to be located in regions involved in
cancer [14] and several examples of an association between
disrupted expression of specific miRNAs and cancer have been
shown in a variety of tissues [15–18]. Lu and collaborators [19]
were the first to observe distinct patterns of miRNA expression
across tumour types, and miRNA profiles reflecting the develop-
mental lineage and the differentiation state of the tumour.
The importance of miRNAs in AML has recently been
emphasised by studies from this laboratory. Using a quantitative
real-time PCR assay specific to the mature miRNA [20], we have
demonstrated that the expression of a limited number of miRNAs
in AML correlates with the AML global expression profile, and
that miR-181a correlates with the morphological subtype and the
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preliminary data illustrate the potential for using miRNA
expression to subclassify cancer. To achieve greater statistical
significance and to provide valuable insights into the oncogenic
process we have now extended this study, and the expression levels
of 157 miRNAs have been measured using the same technology in
an expanded cohort of acute myeloid leukaemias. We demonstrate
that miRNA expression profiles are correlated with the karyotype
in primary adult AML, and that a set of miRNAs is differentially
expressed with respect to normal haematopoietic tissue. We also
developed a method to demonstrate the spatial localisation in situ
of specific miRNAs identified in the quantification, to confirm
their expression with relation to karyotype.
Results
MiRNA expression profiling discriminates karyotypes in
AML
Using a quantitative real-time PCR (qRT-PCR) assay designed to
prime only from the mature miRNA [20], the expression profiles of
157 miRNAs (Table S1) were determined in 100 primary AML
specimens specifically chosen to exhibit the spectrum of known
karyotypes common in AML (Table 1), with examples of AML
FrenchAmericanBritish (FAB) morphological phenotypes[22] from
M1 to M6 (Table S2). Two leukaemic cell lines, KG1 and NB4, and
2 bone marrow samples from healthy donors were also included.
(The median and the normalised Ct values for each miRNA are
reported in Tables S3 and S4, respectively). The data were
normalised as described in the methods section and 34 miRNAs
that were not expressed or did not change in level across the entire
set of samples were excluded from the analysis.
Anunsupervised hierarchical clusteranalysis oftheremaining 123
miRNA expression profiles for 102 leukaemia samples, scaled to the
median of the normal bone marrow controls, revealed molecular
signatures characteristic of the major translocation-mediated gene
fusion events in AML (Figure 1). The most distinctive signature
throughout the whole set of miRNAs was associated with the
promyelocytic leukaemias (APMLs) bearing the t(15;17) transloca-
tion. All but two APML patient samples clustered together showing
high expression of a group of miRNAs. Of the two leukaemia
samples that did not cluster with the other members of the t(15;17)
group, one (patient n. 42) had an additional translocation
t(1;10)(p32;p11.2) and standard M3 morphology, whereas the other
(patient n.94) wasreclassified. At presentation patient n. 94 failed G-
banded analysis but fluorescent in situ hybridisation (FISH) showed a
positive signal for the PML/RARA rearrangement in 38% of cells.
However, within 17 months, the patient was diagnosed with
myelodysplastic syndrome with refractory anemia with excess blasts
(MDS-RAEB). There was no more evidence of a PML/RARA
fusion by FISH, but G-banded analysis revealed the presence of a
t(12;17)(p13;q22) translocation. Samples bearing either the t(8;21)
translocation or the inv(16) were grouped in two distinct clusters of
the same major branch. The 5 AMLs with rearrangement of the
MLL gene at 11q23 were clustered together within the group of
monocytic leukaemias. Leukaemias with a normal karyotype or
other non recurrent rearrangements were split in two major groups
according to their morphological FAB subtype, myelocytic leukae-
mias M1 and M2 and monocytic leukaemias M4 and M5. Within
each cluster the normal karyotype leukaemias were grouped
together. Chromosomal numerical abnormalities did not correlate
with the level of expression of the miRNAs. The 6 samples with an
additional chromosome8 (samplesn.53,55,65,72,75, and100) did
not cluster together and were rather grouped with other samples
according to their morphological subtype. The two cell lines, NB4
and KG1, did not show any similarity with the patient samples and
clustered separately. The unsupervised analysis also split the samples
into two main groups according to their associated cytogenetic
prognostic risk category [3] either favourable or intermediate.
Patient samples with an adverse prognosis were a minority and were
scattered across the set.
Analysis of variance (ANOVA) reveals high expression of
miRNA genes located at 14q32 in APML
To find miRNAs with statistically significant differences in
expression level among the major cytogenetic groups (Table 1), an
ANOVA test was applied to the 102 AML samples, including the
two cell lines. Ninety-four miRNAs passed a 5% false discovery
rate (FDR) filter (Table S5 in the supporting information section).
APMLs bearing the t(15;17) translocation were characterised by
the up regulation of 7 miRNAs transcribed from genes located at
the 14q32 region. The set includes miR-127, miR-154, miR-154*,
miR-299, miR-323, miR-368, and miR-370. The human panel of
157 miRNAs screened in the study included three other miRNAs
located in this region, miR-134, miR-337, and miR-342, but their
expression did not have any statistical significance associated with
APML samples. The NB4 cell line, although bearing the t(15;17)
translocation, did not show expression of any of the miRNAs
located at 14q32. The t(15;17) group of patients was also
characterised by the down regulation of 9 miRNAs (miR-17-3p,
miR-185, miR-187, miR-194, miR-200a, miR-200b, miR-200c, miR-
330, and miR-339). In this case no association with a specific
genome location was observed. Samples with an inv(16) were
characterised by the high level of miR-99a, miR-100, and miR-224,
whereas AMLs carrying a t(8;21) translocation showed a high
expression of miR-146a and a down regulation of miR-133a. The
expression of miR-9 and miR-let7b correlated with the cytogenetic
prognostic risk associated to the samples, being low in the
favourable groups and high in intermediate and adverse
leukaemias. Two miRNAs, miR-10a and miR-125b showed high
degree of variability across the set of samples. The first was not
Table 1. Distribution of the primary chromosomal
aberrations across the set of 100 AMLs.
Primary chromosomal
aberrations Number of samples
t(15;17) Sole aberration 5
With additional cytogenetic changes 4
t(8;21) Sole aberration 5
2X/2Y4
With additional cytogenetic changes 2
inv(16) Sole aberration 4
+22 4
With additional cytogenetic changes 1
11q23 rearrangement t(6;11) 3
t(9;11) 2
Other structural and numerical
aberrations
30
Normal karyotype 36
TOTAL 100
The total number of samples for the sole abnormality or in association with
additional cytogenetic changes are given. (Full patient details are reported in
Table S2 in the supporting information section).
doi:10.1371/journal.pone.0002141.t001
MiRNA Profiles in AML
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a favourable outcome. MiR-125b was mainly expressed in
leukaemias with a normal karyotype.
Differential expression profiles between AMLs and
normal bone marrow controls
A 5% FDR threshold ANOVA test revealed the deregulation of
33 miRNAs across the leukaemic set with respect to bone marrow
from healthy donors (Table 2). Seventeen miRNAs were up
regulated and 16 down regulated in the leukaemia samples.
MiRNAs that are up or down regulated in AMLs are highlighted
in Figure 1 by a red and green bar, respectively, on the left side of
the heatmap.
Validation of pattern of expression of miR-127 and miR-
154 in AML by locked nucleic acid fluorescent in situ
hybridisation (LNA-FISH)
In situ hybridisation using locked nucleic acid (LNA)-modified
probes, digoxigenin (DIG) labelled, permits the visualisation and
spatial localisation of mature miRNAs within a number of tissues
and cell types. These synthetic nucleic acid analogues increase the
thermostability of the nucleic acid duplexes when incorporated
into oligonucleotides [23]. We further developed this methodology
to visualise the spatial localisation of two mature miRNAs, miR-
127 and miR-154, in primary AML suspension cells and thus we
confirmed their high expression in APMLs as measured by real-
time PCR. Seven patient samples (patients n. 104–110) carrying
the t(15;17) translocations were selected based on karyotypic
abnormality and sample availability. Three samples with different
cytogenetics were used as negative controls. One had a normal
karyotype (patient n. 112), patients n. 111 and 113 had a t(9;22)
and a t(8;21) translocation, respectively (Table S2). Digoxigenin
labelled LNA probes were detected using an anti-DIG fluorescein
isothiocyanate (FITC) conjugated antibody and the fluorescent
signals visualised with a confocal microscope which permitted the
spatial localisation of the miRNAs. An example is shown in
Figure 2 for patients n. 109 and n. 111. The expression of miR-127
by LNA-FISH was seen in all samples with a t(15;17) translocation
and in the sample with a t(8;21) translocation. The expression of
Figure 1. Unsupervised hierarchical cluster analysis of 123 miRNA expression profiles for 102 leukaemia samples. Each column
represents a sample, and each row represents a single miRNA. The colour display encodes the logarithm of the expression changes, where varying
shades of red and green indicate up and down regulation, respectively. Values ranged from log2 (210) to log2(+10). MiRNAs passing a 5% FDR
threshold from the leukaemia versus normal bone marrow comparison are highlighted in red or green on the left of the heatmap. Karyotype labels
are also indicated on the top of the heatmap. The colour-key for the labelling is on the top left.
doi:10.1371/journal.pone.0002141.g001
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translocation but not in the 3 patients with other karyotypes. The
detection of both miRNAs was confined to the cytoplasm (Figure 2A
and 2B). Confocal imaging confirmed the nuclear expression of the
small non coding RNA U6 (M14486), chosen as positive control
[24], in all the patient samples (Figure 2C). The scrambled
oligonucleotide was negative in all the samples (Figure 2D). The
number of positive signals for the 4 probes was counted in 100 cells
in each patient and a percentage calculated (Table 3).
Discussion
This study represents a detailed analysis of miRNA expression
in a cohort of 100 primary AMLs. The most striking result is that
AMLs bearing the t(15;17) translocation have a distinctive up
regulation of seven miRNAs located on the human 14q32
imprinted domain. Specific subsets of microRNAs were identified
that provide molecular signatures characteristic of the major
translocation-mediated gene fusion events in AML (Figure 1). It
should be noted that the genes for the seven miRNAs highly
expressed in the samples carrying the t(15;17) translocation are
spread over less than 200,000 bases on chromosome 14q32. They
are organised in clusters together with many other miRNAs not
included in the study [25]. Their imprinted expression, of
maternal origin, is regulated by an intergenic differentially
methylated region (DMR) located ,200 kb upstream from the
miRNA cluster [25]. Epigenetic alteration at the imprinted
domain, defined by DLK1 (AL132711) and GTL2 (AL117190)
genes [26], has been reported in human neoplasia, causing
alteration in the expression of GTL2, although loss of imprinting
for DLK1, has not been found [27,28]. Interestingly, although
included in the same region, three miRNAs did not show an over
expression in the samples with a t(15;17) translocation when
measured by real-time PCR. This might imply a more complex
mechanism of regulation. It has been suggested that miRNAs in
this region act as tumour repressor genes and that changes in the
methylation status of their promoters could trigger cancer
development [29]. For example, miR-127 has been shown to be
expressed, together with other members of its cluster, in normal
tissues [29], but to be down regulated or silenced in cancer cell
lines and primary tumours; the expression is correlated with the
methylation and the acetylation status of its promoter. The use of
inhibitors of methylation and histone deacetylation in these cancer
cells causes over expression of miR-127 and related down
regulation of the target BCL6 (NM_138931), a bona fide proto-
oncogene [29,30]. It is possible that the specific expression of miR-
127 and the other members of the cluster, in a subtype of
leukaemia carrying the t(15;17) translocation, is due to a change in
the methylation and acetylation status of the 14q32 region. The
activation of the expression could be dictated by the developmen-
tal stage of the blast cells, or the chimeric product of the
translocation (PML/RARa) (NM_002675/X06538) could have a
role in the process. Epigenetically regulated expression of miRNA
genes associated with oncogenic function has now been described
for some miRNAs [31,32] and could be true for many more. It is
noteworthy that to our knowledge the over expression of miRNAs
at 14q32 has never been observed to be associated with a specific
subtype of acute myeloid leukaemia, neither in cell lines [33,34],
nor in primary tumours [35–37]. In a recently published work, Mi
and colleagues [36] showed distinct miRNA signatures between
acute lymphoblastic leukaemias (ALLs) and AMLs. The signatures
were grouping the samples according to the major translocation
events in a similar fashion to the study presented here. However,
the set of miRNAs analysed was only partially overlapping, and
the distinct expression of the miRNAs located at 14q32 in the
APML samples was not observed.
It is noticeable that the leukaemic karyotypes other than those
with a t(15;17) were distinguished by the combined differential
pattern of expression of just a few miRNAs. Moreover, some
miRNAs showed high variability across the whole set of AMLs.
Table 2. List of the 33 miRNAs showing different expression levels between leukaemia samples and normal bone marrow.
miRNAs up in AMLs Acc. N. mature miRNA miRNAs down in AMLs Acc. N. mature miRNA
let-7e MIMAT0000066 miR-9* MIMAT0000442
miR-27a MIMAT0000084 miR-15b MIMAT0000417
miR-30d MIMAT0000245 miR-26a MIMAT0000082
miR-142-5p MIMAT0000433 miR-30a-3p MIMAT0000088
miR-155 MIMAT0000646 miR-34c MIMAT0000686
miR-181a MIMAT0000256 miR-103 MIMAT0000101
miR-181b MIMAT0000257 miR-147 MIMAT0000251
miR-181c MIMAT0000258 miR-151 MIMAT0000757
miR-195 MIMAT0000461 miR-182 MIMAT0000259
miR-221 MIMAT0000278 miR-184 MIMAT0000454
miR-222 MIMAT0000279 miR-199a MIMAT0000231
miR-324-5p MIMAT0000761 miR-302b* MIMAT0000714
miR-326 MIMAT0000756 miR-302d MIMAT0000718
miR-328 MIMAT0000752 miR-325 MIMAT0000771
miR-331 MIMAT0000760 miR-367 MIMAT0000719
miR-340 MIMAT0000750 miR-372 MIMAT0000724
miR-374 MIMAT0000727
In the left and right panels are reported the 17 up regulated and the 16 down regulated miRNAs, respectively, in AMLs. (Acc. N.=accession number, Sanger miRBase
database 9/04, Version 5.0, http://microrna.sanger.ac.uk/).
doi:10.1371/journal.pone.0002141.t002
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(NM_005933) gene at 11q23 region, were characterised by the
absence of expression of miR-10a, miR-331, and miR-340. MiR-10a
was also found down regulated in all the leukaemias carrying the
major translocation events, associated with a more favourable
prognosis, and in some cases of AML with a normal karyotype as
we had previously observed [21]. MiR-10a is known to target
HOXA1 (NM_005522) gene [35]. Another miRNA with variable
expression across the set of samples is miR-125b. MiR-125b was
reported down regulated both in breast cancer [38] and in human
prostate cancer [39]. It targets ERBB2 and ERBB3 in human
breast cancer cell lines [40] and its depletion is critical for the
proliferation of differentiated cells.
The comparison of the leukaemia samples with bone marrow
from healthy donors highlighted the differential expression of a
number of miRNAs potentially involved in the oncogenic process.
Among the up regulated miRNAs in AMLs, a number were
already known to be haematopoietic tissue-specific, i.e. miR-142-
Table 3. Percentage of positive cells for each LNA probe in 10 AMLs.
n. 104 n. 105 n. 106 n. 107 n. 108 n. 109 n. 110 n. 111 n. 112 n. 113
t(15;17) t(15;17) t(15;17) t(15;17) t(15;17) t(15;17) t(15;17) t(9;22) NK t(8;21)
miR-127 25 76 27 95 55 84 84 ,5 ,52 5
miR-154 10 38 23 33 58 55 35 ,5 ,5 ,5
U6 (+ve ctrl) 82 75 78 81 78 88 84 84 100 80
2ve ctrl ,5 ,5 ,5 ,5 ,5 ,5 ,5 ,5 ,5 ,5
A simplified karyotype is reported in italics. NK=normal karyotype.
doi:10.1371/journal.pone.0002141.t003
Figure 2. MiRNA detection in cryopreserved bone marrow cells by LNA-FISH. Patients n. 109 (lanes 1–3) and n. 111 (lanes 4–6) carrying the
t(15;17) and t(9;22) translocations, respectively, are shown. All images were obtained with the confocal microscope as described in the method. The
DAPI nuclear staining (blue), the fluorescent in situ hybridisation signals obtained with FITC-conjugated antibody (green), and the combined images
are indicated. The A and B panels show the detection of miR-127 and miR-154, respectively. Both miRNAs are detected in the cytoplasm of cells (lanes
2 and 3) of patient n. 109 but not in patient n. 111 (lanes 5 and 6). The C panel shows the nuclear expression of U6, the small RNA used as positive
control, in both samples (lanes 2 and 5). No signal was detected when cells were hybridised with a scrambled oligonucleotide (negative control), as
shows in lanes 2 and 5 of the D panel.
doi:10.1371/journal.pone.0002141.g002
MiRNA Profiles in AML
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expressed in a variety of haematological malignancies and solid
tumours, i.e. miR-221, and miR-222. In particular, miR-155,a
negative regulator of normal myelopoiesis and erythropoiesis [41],
was first observed highly expressed in paediatric Burkitt lympho-
mas [17]. Later, over expression of miR-155 was reported in other
haematological malignancies [43], and in solid tumours [44]. MiR-
181a, absent in B-cell chronic lymphocytic leukaemia (B-CLL) and
mature B cells [42], known to inhibit the differentiation of all
haematopoietic lineages [41], was also found associated with a
specific leukaemic phenotype [21] in AMLs with a normal
karyotype. MiR-181 regulates the expression of TCL1 (X82240) in
CLL [45]. MiR-221 and miR-222, involved in the negative control of
human erythropoiesis byblocking the C-Kit(S67773) gene [46], have
been reported to be highly expressed in a variety of solid tumours
including colon, pancreas, and prostate cancers [44,47]. In some of
these cases, miR-221 has been shown to block the expression of a cell
cycle inhibitor and tumour suppressor gene, p27(Kip1) (AF480891)
[48], reinforcing the hypothesis of its oncogenic role. Isken and
colleagues[37] have alsoreported asignificantlyhigherexpression of
miR-221 and miR-222 in AML blasts.
It is notable that, among the 16 down regulated miRNAs (with
respect to the normal controls) 5 miRNAs were previously
described as having an anti-oncogenic role. For example miR-
34c, a target of p53, was shown to cooperate in suppressing
proliferation and soft-agar colony formation of neoplastic
epithelial ovarian cells [49]. MiR-184 was found down regulated
in paediatric neuroblastomas with MYCN (NM_005378) amplifi-
cation and poorer prognoses [50]. Also down regulated were miR-
26a and miR-199a, both described as potential tumour suppressor
genes in a recent study analysing the expression of 241 human
miRNAs in normal tissues and in the NCI-60 panel of human
tumour-derived cell lines [34]. Other down regulated miRNAs in
the leukaemia samples but with different functions include miR-
103 and miR-372. The first is known to act in the differentiation of
granulocytic, monocytic, and B-lymphoid lineages [41], and its
down regulation might have a role in the differentiation block
typical of leukaemias. MiR-372 is a potential oncogene involved in
the human testicular germ cell tumour through the deactivation of
the p53 pathway [51].
This is the first time, to our knowledge, that in situ fluorescent
hybridisation using DIG labelled LNA probes has been used for the
local visualisation of mature miRNAs in haematopoietic suspension
cells. The LNA probe hybridisation yields highly accurate signals
able to discriminate between single nucleotide differences and hence
between closely related miRNA family members [23,52]. Compared
to other techniques such as northern blots, it offers the possibility to
detect miRNAs in a sparse population of cells. The selected
miRNAs, miR-127 and miR-154, were clearly visualised and
compared in different leukaemic subtypes, providing a validation
of the real-time PCR measurement.
This study, conducted on about a fifth of the miRNAs currently
reported in the Sanger database (microrna.sanger.ac.uk), demon-
strates the potential for using miRNA expression to subclassify
cancer, and suggests that miRNAs might play an important role in
the molecular pathogenesis of AML interfering with pathways
essential at various stages of haematopoiesis.
Materials and Methods
Patient samples and controls
This study was performed using archival material. One hundred
and ten peripheral blood (PB) or bone marrow (BM) samples from
AML patients were obtained from the St Bartholomew’s Hospital
tissue bank. The diagnosis of leukaemia was made based on clinical
presentation and morphological analysis as previously described [5].
The average blast percentage for these samples was 63% with a
median value of 83%. (Full sample information, including French
American British (FAB) morphological subtype [22] and cytogenetic
karyotypes are reported in Table S2). RNA was extracted from 2
BM samples from healthy donors. Two leukaemic cell lines were
included KG1 (a cell line derived from a patient with erythroleu-
kaemia in myeloblastic relapse) and NB4 (a cell line derived from a
patient with acute promyelocytic leukaemia).
Written informed consent was obtained from all the patients,
when possible, to store the excess diagnostic tissue for research
purposes. When patient consent was not obtained because of
death, patient anonymity was preserved. Ethical approval to access
the stored material and perform the study described here was
obtained from the East London and The City Health Authority
Research Ethics Committee (P1/03/133).
Cell culture
Fresh patient samples were either immediately processed for
RNA extraction or cryopreserved following Lymphoprep
TM (Axis-
Shield, Norway) separation and therefore did not require
culturing. Cell lines, KG1 and NB4, were cultured and maintained
in RPMI 1640 medium with Glutamax (GIBCO, Invitrogen,
Carlsbad, CA) supplemented with 10% heat-inactivated foetal calf
serum (GIBCO) and 1% penicillin/streptomycin antibiotics at
37uC in a humidified atmosphere containing 5% CO2. All cultures
passed mycoplasma testing.
Quantitative real-time PCR assay
Total RNA was extracted from fresh or cryopreserved patient
samples, either BM or PB, using TRIzol (Invitrogen Life
Technologies) according to manufacturer’s instructions. Samples
were reverse transcribed using the TaqManHMicroRNA Reverse
Transcription Kit (P/N 4366597, Applied Biosystems) and mature
miRNAs were quantified by real-time PCR using the TaqManH
MicroRNA Assays - Human Panel Early Access Kit (P/N
4365409, Applied Biosystems) [20] as previously described [21].
The kit contained assays for 157 miRNAs (Table S1) of the 733
currently listed in the Sanger miRBase database [53]. Reactions
for patient samples n. 1 to 100, the 2 normal BM samples, and the
2 cell lines, were prepared using a BiomekHFx Laboratory
Automation Workstation (Beckman Coulter, Inc) and volumes
adapted as necessary. The reaction mixtures were prepared in
triplicate in two 384-well plates, A and B. For patient samples n.
104 to 113, real-time PCR reactions were manually prepared
using TaqManH individual MicroRNA Assays (Applied Biosys-
tems) for miR-127 (P/N 4373147), miR-154 (P/N 4373270), and
miR-16 (P/N 4373121). Reactions were performed in triplicate as
described above. All the PCR reactions were performed using an
ABI 7900HT Sequence Detection System.
Data analysis
Undetermined raw Ct values were set to 40. Median Ct
replicate values were calculated and each plate scaled to the
negative plate median Ct value. Prior to analysis, miRNAs
displaying a coefficient of variance less than 0.15 across all samples
were excluded along with miRNAs with a normalised Ct value less
than 0 in all samples. After this 123 miRNAs remained. Plates A
and B for each sample were merged. In the unsupervised two-
dimensional cluster analysis, the 123 miRNA expression profiles
for 102 leukaemia samples were scaled to the median of the
normal bone marrow controls. MiRNAs and samples were
clustered using complete linkage and euclidean distance. Analysis
MiRNA Profiles in AML
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rate (FDR) threshold to identify differentially expressed miRNAs
between leukaemia samples and normal bone marrow. MiRNAs
specific to karyotype groupings were identified in the same way.
The analysis was carried out using the limma package from
Bioconductor [54].
Locked nucleic acid fluorescent in situ hybridisation
(LNA-FISH)
Locked nucleic acid (LNA)-modified probes were obtained for
two miRNAs (miR-127 and miR-154) and positive (U6) and nega-
tive controls (miRCURY-LNA detection probe, Exiqon). The
probe sequences were (59-39): miR-154, CGAAGGCAACACG-
GATAACCTA; miR-127, AGCCAAGCTCAGACGGAT-
CCGA; U6, CACGAATTTGCGTGTCATCCTT. A scrambled
oligonucleotide was used as negative control: TTCACAATG-
CGTTATCGGATGT. Full detailed probe labelling and hybrid-
isation protocols are described in Protocol S1 in the Supporting
Information section. Briefly, LNA detection probes were labelled
with digoxigenin (DIG) using a DIG 39end labelling kit (P/N
03353583910, Roche). One hundred ml of 0.5 million cells/ml
from thawed BM or PB was pipetted into a cytospin column and
spun on poly-l-lysine coated glass slides. After application of 200 ml
of the hybridisation mixture containing ,30 ng/ml of labelled
probe, slides were incubated for 17–18 hours at a temperature 20–
22uC below the melting temperature (Tm) of the miRCURY LNA
probe used in a humidified HYBrite
TM (Abbott Laboratories Ltd).
Slides were extensively washed and then incubated for 1 hour at
37uC with anti-DIG fluorescein isothiocynate (FITC) conjugated
antibody, washed again, drained and counterstained with 49-
69Diamidino-2-phenylindole (DAPI), before the addition of
ProLongH Gold antifade reagent (Invitrogen).
Microscopy and image analysis
LNA-FISH signals were visualised on a Zeiss 510 Meta confocal
microscope equipped with a Plan-Apochromat 636/1.4OilDIC
lens, fitted with a motorised stage. One hundred cells were assessed
for each probe. Image stacks of cells were captured and analysed
using programs LSM510, version 3.2SP2 and Image J, version
1.39d (http://rsb.info.nih.gov/ij/index.html).
Supporting Information
Table S1 List of the 157 human miRNAs included in the study.
The miRNAs analysed in the work, reported here alongside their
accession number and sequence, were selected from the Sanger
miRBase database v5.0, Sept 2004, http://microrna.sanger.ac.
uk/. (n/a refers to miRNAs currently removed from the database).
Found at: doi:10.1371/journal.pone.0002141.s001 (0.05 MB
PDF)
Table S2 AML patient details. Sex, age at diagnosis, percentage
of blasts, morphological FAB subtype, and karyotype are reported.
(BM=bone marrow; PB=peripheral blood; MDS=myelodys-
plastic syndrome; RAEB=refractory anemia with excess blasts).
Found at: doi:10.1371/journal.pone.0002141.s002 (0.05 MB
PDF)
Table S3 Real-time PCR results, raw data. The spreadsheet
contains the median Ct values of 157 miRNAs quantified in 100
AML samples, 2 cell lines (NB4 and KG1), and 2 normal bone
marrow controls (NBM4 and NBM5).
Found at: doi:10.1371/journal.pone.0002141.s003 (0.25 MB
PDF)
Table S4 Real-time PCR results, normalised data. The
spreadsheet contains the values of 123 miRNAs after normalisa-
tion for 100 AML samples, 2 cell lines (NB4 and KG1), and 2
normal bone marrow controls (NBM4 and NBM5). Median Ct
values were normalised to the negative plate median (as described
in the method section of the manuscript) so negative values are the
low abundant miRNAs, positive the more abundant.
Found at: doi:10.1371/journal.pone.0002141.s004 (0.24 MB
PDF)
Table S5 List of the 94 miRNAs that passed the 5% FDR filter
in the ANOVA test. The miRNAs are reported alongside their
accession number and sequence (Sanger miRBase database v5.0,
Sept 2004, http://microrna.sanger.ac.uk/. n/a refers to miRNAs
removed from the Registry).
Found at: doi:10.1371/journal.pone.0002141.s005 (0.04 MB
PDF)
Protocol S1 Locked nucleic acid fluorescent in situ hybridisation
(LNA-FISH) detailed protocol.
Found at: doi:10.1371/journal.pone.0002141.s006 (0.05 MB
DOC)
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